inosineFinding
Inosine increases progression-free survival
raisesModerate evidenceFinding
01 · The sentence it was drawn from
“Compared with the control group, the 6‐ and 12‐month PFS rates were significantly higher in the inosine group (Table 2).”
inosine
Progression- free survival
raises
- Who
- Adults aged 18-75 with advanced (locally advanced, recurrent, metastatic or unresectable) malignant solid tumours receiving PD-1/PD-L1 inhibitor therapy, with or without targeted therapy or chemotherapy, in both arms; PFS rates at the 6- and 12-month landmarks
- Dose studied
- inosine tablets, 0.2 g three times daily, added to PD-1/PD-L1 inhibitor regimen until progression or unacceptable toxicity
Moderate evidencePMID 39267574 · 2024
02 · The study
- Study
- RCT
- Duration
- not reported
Evidence, by strength
- strong
- moderatethis finding
- limited
- very limited
- insufficient
03 · The paper
Cancer medicine04 · To cite this finding
This address does not changehttps://catalystproject.ai/e/01M7GGMBKVJDAYZEHE4AYRZGBN